Tech Company Financing Transactions
Synereca Pharmaceuticals Funding Round
Accele BioPharma and i2e Enterprise Oklahoma Fund joined a $1.4 million venture round for Synereca Pharmaceuticals. The round closed on 9/17/2014.
Transaction Overview
Company Name
Announced On
9/17/2014
Transaction Type
Venture Equity
Amount
$1,400,000
Round
Undisclosed
Investors
Accele BioPharma (Lead Investor)
Proceeds Purpose
Proceeds of the financing will be used to advance SPI's research focused on compounds to potentiate the effectiveness of existing antibiotics against drug-resistant Gram-negative bacteria.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
865 Research Parkway 400
Oklahoma City, OK 73104
USA
Oklahoma City, OK 73104
USA
Phone
Website
Email Address
Overview
Synereca Pharmaceuticals was created to address the growing problem of bacterial resistance to current antibiotics by developing orally active drugs that restore or increase the effectiveness of existing antibiotics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Clayton Duncan
Chief Financial Officer
Kelle Jones
Chief Operating Officer
Richard Gammans
Chief Scientific Officer
Scott Singleton
VP - Operations
Bennett Love
VP - R & D
Stephen Bocckino
Browse more venture capital transactions:
Prev: 9/17/2014: Crystalplex venture capital transaction
Next: 9/17/2014: Talkdesk venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs